Steward Partners Investment Advisory’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Steward Partners Investment Advisory’s Portfolio TMBR Stock Details TMBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$2	–	3494
2023 Q2	$2	Hold	1	–	–	﹤0.01%	3318
2023 Q1	$2	Hold	1	–	–	﹤0.01%	3306
2022 Q4	$2	Hold	1	–	–	﹤0.01%	3351
2022 Q3	$0	Hold	1	–	–	﹤0.01%	3482
2022 Q2	$0	Buy	+1	New	+$15	﹤0.01%	3457

Other funds holding TMBR

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Steward Partners Investment Advisory's TMBR Position: Q3 2023 in Review

Steward Partners Investment Advisory sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2023, closing a stake of 1 share — an estimated $2 sold.

Steward Partners Investment Advisory first reported a position in TMBR in Q2 2022 and held it in 5 quarters. The position peaked at $2 in Q2 2023. 11 funds tracked by Wall St. Rank hold TMBR as of Q3 2023.

Steward Partners Investment Advisory reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Steward Partners Investment Advisory sold 1 Timber Pharmaceuticals, Inc. share in Q3 2023, an estimated $2.
Steward Partners Investment Advisory first reported a position in Timber Pharmaceuticals, Inc. in Q2 2022 and held it in 5 quarters.
Steward Partners Investment Advisory's Timber Pharmaceuticals, Inc. position peaked at $2 in Q2 2023.
11 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2023, filed 13 Nov 2023.